Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer

Daniele Oddo, Erin M. Sennott, Ludovic Barault, Emanuele Valtorta, Sabrina Arena, Andrea Cassingena, Genny Filiciotto, Giulia Marzolla, Elena Elez, Robin M J M Van Geel, Alice Bartolini, Giovanni Crisafulli, Valentina Boscaro, Jason T. Godfrey, Michela Buscarino, Carlotta Cancelliere, Michael Linnebacher, Giorgio Corti, Mauro Truini, Giulia SiravegnaJulieta Grasselli, Margherita Gallicchio, René Bernards, Jan H M Schellens, Josep Tabernero, Jeffrey A. Engelman, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Ryan B. Corcoran, Federica Di Nicolantonio

Research output: Contribution to journalArticle

Abstract

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of BRAF-mutant resistant cell line models across seven different clinically relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental-sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway. Genotyping of resistant cells identified gene amplification of EGFR, KRAS, and mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1. These mechanisms were clinically relevant, as we identified emergence of a KRAS G12C mutation and increase of mutant BRAF V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors. To identify therapeutic combinations capable of overcoming drug resistance, we performed a systematic assessment of candidate therapies across the panel of resistant cell lines. Independent of the molecular alteration acquired upon drug pressure, most resistant cells retained sensitivity to vertical MAPK pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were applied. These therapeutic combinations represent promising strategies for future clinical trials in BRAF-mutant colorectal cancer.

Original languageEnglish
Pages (from-to)4504-4515
Number of pages12
JournalCancer Research
Volume76
Issue number15
DOIs
Publication statusPublished - Aug 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., Van Geel, R. M. J. M., Bartolini, A., Crisafulli, G., Boscaro, V., Godfrey, J. T., Buscarino, M., Cancelliere, C., Linnebacher, M., Corti, G., Truini, M., ... Di Nicolantonio, F. (2016). Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Research, 76(15), 4504-4515. https://doi.org/10.1158/0008-5472.CAN-16-0396